Follow The Filings

ACTU Actuate Therapeutics

Actuate Therapeutics earnings company data as of 7:04 PM ET 11/20

  • 1 of 2 EPS beats

History

2 periods, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 13 Nov EPS -0.17 -0.14 Beat
Rev — — —
FY2026 Q2 14 Aug EPS -0.20 -0.20 Miss
Rev — — —

Insider trades

Open-market buys and sales by ACTU's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ACTU insider trades
  • None no insider bought on the open market
  • $1.6M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Daniel M. Schmitt CEO
    Buy
    — 140,844 shares +47% to stake
    Traded Oct 28 Filed Oct 29
  2. Todd S. Thomson Director, +1 joint filer
    Sale
    $1.6M 280,000 shares at $5.80 24% of stake
    Traded Jan 5 Filed Jan 7

Also filed in the last 12 months, not counted as buying or selling: 2 share withholdings for taxes and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 23 shown.

Filed Form Detail Links
10-Q FORM 10-Q SEP 2026
SCHEDULE 13G —
8-K 3.01
8-K 1.01,8.01,9.01
424B5 FORM 424B5
S-1/A FORM S-1 AMENDMENT
S-1/A FORM S-1 AMENDMENT
S-1 REGISTRATION STATEMENT
10-Q FORM 10-Q FOR JUN 2026
8-K 3.01
8-K 5.07
10-Q FORM 10-Q FOR MAR 2026
8-K 7.01,9.01
8-K 5.02,8.01,9.01
DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS
SCHEDULE 13G/A —
DEF 14A
DEFA14A
10-K FORM 10-K FOR DEC 2025
8-K 7.01,9.01
SCHEDULE 13G —
424B5 SUPPLEMENT TO PROSPECTUS DATED 9-8-25
8-K 1.01,9.01

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf